Company profile
ARGENX SE
NASDAQ:ARGXBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (5)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| VYVGART | approved | — | 15 | approved |
| VYVGART HYTRULO | approved | — | 0 | — |
| VYVGART HYTRULO | approved | — | 0 | — |
| EMPASIPRUBART | phase3 | — | 6 | active |
| ADIMANEBART | phase2 | — | 3 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (74)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05405361 | phase2 | active_not_recruiting | 2023-01-18 | 2029-09-30 | argenx | A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy |
| NCT05225675 | phase2 | completed | 2022-03-31 | 2024-06-04 | argenx | A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy |
| NCT05670704 | phase1 | completed | 2023-02-21 | 2024-08-08 | argenx | A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy Participants |
| NCT04225156 | phase3 | completed | 2020-06-02 | 2026-03-11 | argenx | A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). |
| NCT05817435 | phase1 | completed | 2023-03-13 | 2023-05-12 | argenx | A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults |
FDA applications (2)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 761304 | 2023-06-20 | BLA | ARGENX BV | |||||
Loading… | ||||||||
| BLA 761195 | 2021-12-17 | BLA | ARGENX BV | |||||
Loading… | ||||||||